Compare Novavax Inc (NVAX) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Toronto-Dominion Bank — how do they compare? Novavax Inc trades at $7.96 (market cap $1.31B), while Toronto-Dominion Bank trades at $121.35 (market cap $200.48B). The key difference: Toronto-Dominion Bank is far larger — about 153× Novavax Inc's market cap, and Toronto-Dominion Bank pays a 2.63% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | TD | |
|---|---|---|
Market Cap | $1.31B | $200.48B |
Sector | Health | Financials |
52-Week High | $11.19 | $124.80 |
52-Week Low | $6.22 | $72.85 |
Enterprise Value | $889.30M | — |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
TD trades at $123.38, up 1.9% today, with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $1.70. Revenue grew to $61.28 billion in 2025, and the net income margin improved to 33.51%. A dividend of $1.12 is scheduled for payment on July 31, 2026.
The outlook is positive, supported by strong earnings momentum and a unanimous analyst buy/hold consensus with no sell ratings. Key risks include volatile cash flows from operations and high leverage, with total liabilities of $1.95 trillion. The stock offers value with a P/E of 19.88 and robust profitability metrics like ROE of 12.59%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
